KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $811.0 million.

  • Gilead Sciences' Change in Accured Expenses rose 43355.26% to $811.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $706.0 million, marking a year-over-year increase of 48833.33%. This contributed to the annual value of $108.0 million for FY2024, which is 7641.92% down from last year.
  • Latest data reveals that Gilead Sciences reported Change in Accured Expenses of $811.0 million as of Q3 2025, which was up 43355.26% from -$166.0 million recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Change in Accured Expenses ranged from a high of $1.5 billion in Q4 2021 and a low of -$1.7 billion during Q1 2022
  • In the last 5 years, Gilead Sciences' Change in Accured Expenses had a median value of $50.0 million in 2023 and averaged $46.4 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 19517.24% in 2021, then skyrocketed by 134800.0% in 2022.
  • Quarter analysis of 5 years shows Gilead Sciences' Change in Accured Expenses stood at $1.5 billion in 2021, then crashed by 76.88% to $356.0 million in 2022, then decreased by 10.96% to $317.0 million in 2023, then decreased by 3.79% to $305.0 million in 2024, then surged by 165.9% to $811.0 million in 2025.
  • Its last three reported values are $811.0 million in Q3 2025, -$166.0 million for Q2 2025, and -$244.0 million during Q1 2025.